Dr. Raghuram Selvaraju is a Managing Director of Equity Research at H.C. Wainwright whose research focuses on the healthcare sector. Dr. Selvaraju possesses over a decade’s worth of experience in Healthcare Equity Research. Dr. Selvaraju was ranked by both the StarMine for his earnings accuracy and by The Wall Street journal’s annual Best on the Street Analyst for his stock-picking performance. In addition, Dr. Selvaraju has appeared numerous times on Bloomberg, CNBC, Business News Network and BTV where he discussed drug development trends, healthcare reform policy, and pharma and biotech M&A.
Prior to joining H.C. Wainwright, Dr. Selvaraju held Senior Research positions at MLV & Co., Aegis Capital, Hapoalim Securities USA and Rodman & Renshaw LLC. Dr. Selvaraju’s educational background includes a Ph.D. in molecular neuroscience and cellular immunology, an M.S. degree in molecular biology from the University of Geneva in Switzerland, and an MBA from Cornell University.